ABL, a global contract research and manufacturing service provider to the U.S. Government and biopharmaceutical industry, has been awarded a five-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSO100201600019I entitled, “Respiratory Illness Live Virus Fill/Finish Services,” by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS).

The contract has a maximum ordering amount of $50 million and is part of a multiple award network to provide fill/finish capabilities for live virus-based medical countermeasure (MCM) product development towards licensure. ABL will utilize its GMP facilities located in Rockville, MD, and Strasbourg, France, each site staffed with manufacturing, bioanalytical and quality assurance teams with extensive experience producing vaccine, therapeutic and diagnostic products.

“We are very excited to be supporting BARDA and ASPR for the rapid development and manufacture of vaccines and therapeutics against potential pandemic and emerging disease targets,” said Thomas VanCott, president and chief executive officer, ABL. “ABL provides bulk and filling capabilities specifically designed to handle live virus products, and with facilities in Europe and the U.S., we are ideally positioned to meet BARDA’s MCM requirements.”

ABL’s fill and finish drug manufacturing capabilities meet U.S. FDA and European GMP requirements for a wide variety of live/vectored products at pilot, clinical, and commercial scales.